Placebo group | N | LGG group | N | P | |
---|---|---|---|---|---|
Rotavirus | 33 (39.3%) | 84 | 22 (24.4%) | 90 | 0.052 |
EPEC | 12 (17.6%) | 68 | 9 (13.2%) | 68 | 0.635 |
Vibrio cholerae | 7 (8.0%) | 88 | 11 (12.4%) | 89 | 0.471 |
Campylobacter sp. | 6 (6.8%) | 88 | 9 (10.1%) | 89 | 0.605 |
Shigella sp. | 9 (10.2%) | 88 | 4 (4.5%) | 89 | 0.241 |
Aeromonas sp. | 2 (2.3%) | 88 | 1 (1.1%) | 89 | 0.992 |
Salmonella sp. | 0 (0.0%) | 88 | 1 (1.1%) | 89 | 0.995 |
Negative microbiology | 25 (36.8%) | 68 | 32 (47.1%) | 68 | 0.452 |
Cryptosporidium parvum | 6 (7.0%) | 86 | 2 (2.2%) | 89 | 0.256 |
Giardia lambliae | 2 (2.3%) | 86 | 3 (3.4%) | 89 | 0.969 |
Strongyloides stercolaris | 1 (1.2%) | 86 | 0 (0.0%) | 89 | 0.986 |
Trichomonas sp. | 0 (0.0%) | 86 | 2 (2.2%) | 89 | 0.492 |
Negative parasitology | 77 (89.5%) | 86 | 82 (92.1%) | 89 | 0.738 |
Negative microbiology and parasitology | 22 (35.5%) | 62 | 30 (44.8%) | 67 | 0.371 |